Aethlon Medical is a medical technology company. The Aethlon Hemopurifier® is a clinical-stage immunotherapeutic device designed to combat cancer and life-threatening viral infections. The U.S. Food and Drug Administration has designated the Hemopurifier as a Breakthrough Device for two independent indications: the treatment of individuals with metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate in the development or severity of the disease; and the treatment of life-threatening viruses that are not addressed with approved therapies. The AEMD stock yearly return is shown above.
The yearly return on the AEMD stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2020 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the AEMD annual return calculation with any dividends reinvested as applicable (on ex-dates).
|